Protective antibody responses elicited by a meningococcal outer membrane vesicle vaccine with overexpressed genome-derived neisserial antigen 1870.
Open Access
- 15 August 2005
- journal article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 192 (4) , 580-590
- https://doi.org/10.1086/432102
Abstract
BackgroundMeningococcal outer membrane vesicle (OMV) vaccines are efficacious in humans but have serosubtype-specific serum bactericidal antibody responses directed at the porin protein PorA and the potential for immune selection of PorA-escape mutants MethodsWe prepared an OMV vaccine from a Neisseria meningitidis strain engineered to overexpress genome-derived neisserial antigen (GNA) 1870, a lipoprotein discovered by genome mining that is being investigated for use in a vaccine ResultsMice immunized with the modified GNA1870-OMV vaccine developed broader serum bactericidal antibody responses than control mice immunized with a recombinant GNA1870 protein vaccine or an OMV vaccine prepared from wild-type N. meningitidis or a combination of vaccines prepared from wild-type N. meningitidis and recombinant protein. Antiserum from mice immunized with the modified GNA1870-OMV vaccine also elicited greater deposition of human C3 complement on the surface of live N. meningitidis bacteria and greater passive protective activity against meningococcal bacteremia in infant rats. A N. meningitidis mutant with decreased expression of PorA was more susceptible to bactericidal activity of anti-GNA1870 antibodies ConclusionsThe modified GNA1870-OMV vaccine elicits broader protection against meningococcal disease than recombinant GNA1870 protein or conventional OMV vaccines and also has less risk of selection of PorA-escape mutants than a conventional OMV vaccineKeywords
This publication has 32 references indexed in Scilit:
- The Region Comprising Amino Acids 100 to 255 ofNeisseria meningitidisLipoprotein GNA 1870 Elicits Bactericidal AntibodiesInfection and Immunity, 2005
- Functional Activity of Anti-Neisserial Surface Protein A Monoclonal Antibodies against Strains ofNeisseria meningitidisSerogroup BInfection and Immunity, 2001
- Importance of Complement Source in Measuring Meningococcal Bactericidal TitersClinical and Diagnostic Laboratory Immunology, 2001
- Multiple Mechanisms of Phase Variation of PorA in Neisseria meningitidisInfection and Immunity, 2000
- Diversity and Prevalence of PorA Types inNeisseria meningitidisSerogroup B in the United States, 1992–1998The Journal of Infectious Diseases, 2000
- Sequence Variation in the porA Gene of a Clone of Neisseria meningitidis during Epidemic SpreadClinical and Diagnostic Laboratory Immunology, 2000
- Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccineVaccine, 2000
- Identification of Vaccine Candidates Against Serogroup B Meningococcus by Whole-Genome SequencingScience, 2000
- Stable shuttle vectors for Neisseria gonorrhoeae, Haemophilus spp. and other bacteria based on a single origin of replicationGene, 2000
- Murine Immune Response toNeisseria meningitidisGroup C Capsular Polysaccharide: Analysis of Monoclonal Antibodies Generated in Response to a Thymus-Independent Antigen and a Thymus-Dependent Toxoid Conjugate VaccineInfection and Immunity, 2000